more

Hikma Pharmaceuticals (HKMPF)

(Delayed Data from OTC)

$22.33 USD

0.00 (0.00%)

Updated Apr 17, 2024 09:49 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.20%
2	Buy	18.04%
3	Hold	9.52%
4	Sell	5.20%
5	Strong Sell	2.60%
S&P	500	11.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5 4

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

Bottom 42% (147 out of 252)

Industry: Medical - Drugs

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Hikma Pharmaceuticals Plc (HKMPF) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research Published on September 28,2021

Hikma Pharmaceuticals Plc (HKMPF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

HKMPFNo Net Change

Here's Why "Trend" Investors Would Love Betting on Hikma Pharmaceuticals Plc (HKMPF)

by Zacks Equity Research Published on May 24,2021

Hikma Pharmaceuticals Plc (HKMPF) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

HKMPFNo Net Change

Pacira (PCRX) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research Published on July 02,2020

Pacira (PCRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Rigel Pharmaceuticals (RIGL) Looks Good: Stock Adds 9.7% in Session

by Zacks Equity Research Published on June 26,2020

Rigel Pharmaceuticals (RIGL) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

medical

HKMPF vs. NBIX: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research Published on September 05,2019

HKMPF vs. NBIX: Which Stock Is the Better Value Option?

Lannett (LCI) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research Published on September 04,2019

Lannett (LCI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

HKMPF or ZTS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research Published on August 14,2019

HKMPF vs. ZTS: Which Stock Is the Better Value Option?

Ironwood Commences Phase I Study on IW-6463 for CNS Disorders

by Zacks Equity Research Published on January 24,2019

Ironwood (IRWD) begins a phase I study on CNS-penetrant soluble guanylate cyclase stimulator, IW-6463, for treating severe CNS disorders.

medical

Ocular (OCUL) Submits an sNDA for Eye Pain Drug Dextenza

by Zacks Equity Research Published on January 11,2019

Ocular (OCUL) files an sNDA to the FDA for expanding the label of its eye drug, Dextenza, to treat ocular inflammation post ophthalmic surgery.

medical

Karyopharm Files MAA for Myeloma Candidate Selinexor in EU

by Zacks Equity Research Published on January 09,2019

Karyopharm (KPTI) tenders a marketing application to European regulatory authority with the purpose of seeking an approval for selinexor to address patients with penta-refractory multiple myeloma.

medical

Neurocrine Gives Ingrezza Sales View, Updates on Pipeline

by Zacks Equity Research Published on January 07,2019

Neurocrine (NBIX) issues preliminary sales outlook for Ingrezza with respect to the fourth quarter of 2018 as well as the full year. The company also lends an update on its pipeline.

medical

Spectrum Pharma Fully Enrolls 1St Cohort in Poziotinib Study

by Zacks Equity Research Published on January 03,2019

Spectrum Pharma (SPPI) completes enrollment in the first cohort of a phase II study on poziotinib for previously treated NSCLC patients with EGFR exon 20 insertion mutations. Shares rise.

medical

Flexion Starts Phase III Enrollment on Zilretta for Hip OA

by Zacks Equity Research Published on January 03,2019

Flexion (FLXN) initiates enrollment in phase III study on its pain drug, Zilretta, for the treatment of patients suffering hip osteoarthritis.

medical

Spectrum Pharma Files BLA for Neutropenia Candidate Rolontis

by Zacks Equity Research Published on December 28,2018

Spectrum Pharma (SPPI) petitions for a BLA to the FDA regarding its lead pipeline candidate, Rolontis, to address chemotherapy-induced neutropenia in patients with breast cancer.